Matthew W Johnson1, Albert Garcia-Romeu1, Roland R Griffiths1,2. 1. a Department of Psychiatry and Behavioral Sciences , Johns Hopkins University School of Medicine , Baltimore , MD , USA. 2. b Department of Neuroscience , Johns Hopkins University School of Medicine , Baltimore , MD , USA.
Abstract
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. METHODS: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. RESULTS: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. CONCLUSION: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
BACKGROUND: A recent open-label pilot study (N = 15) found that two to three moderate to high doses (20 and 30 mg/70 kg) of the serotonin 2A receptor agonist, psilocybin, in combination with cognitive behavioral therapy (CBT) for smoking cessation, resulted in substantially higher 6-month smoking abstinence rates than are typically observed with other medications or CBT alone. OBJECTIVES: To assess long-term effects of a psilocybin-facilitated smoking cessation program at ≥12 months after psilocybin administration. METHODS: The present report describes biologically verified smoking abstinence outcomes of the previous pilot study at ≥12 months, and related data on subjective effects of psilocybin. RESULTS: All 15 participants completed a 12-month follow-up, and 12 (80%) returned for a long-term (≥16 months) follow-up, with a mean interval of 30 months (range = 16-57 months) between target-quit date (i.e., first psilocybin session) and long-term follow-up. At 12-month follow-up, 10 participants (67%) were confirmed as smoking abstinent. At long-term follow-up, nine participants (60%) were confirmed as smoking abstinent. At 12-month follow-up 13 participants (86.7%) rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives. CONCLUSION: These results suggest that in the context of a structured treatment program, psilocybin holds considerable promise in promoting long-term smoking abstinence. The present study adds to recent and historical evidence suggesting high success rates when using classic psychedelics in the treatment of addiction. Further research investigating psilocybin-facilitated treatment of substance use disorders is warranted.
Authors: Salvatore Mottillo; Kristian B Filion; Patrick Bélisle; Lawrence Joseph; André Gervais; Jennifer O'Loughlin; Gilles Paradis; Robert Pihl; Louise Pilote; Stephane Rinfret; Michèle Tremblay; Mark J Eisenberg Journal: Eur Heart J Date: 2008-12-24 Impact factor: 29.983
Authors: Michael P Bogenschutz; Alyssa A Forcehimes; Jessica A Pommy; Claire E Wilcox; P C R Barbosa; Rick J Strassman Journal: J Psychopharmacol Date: 2015-01-13 Impact factor: 4.153
Authors: David Gonzales; Donovan Redtomahawk; Barbara Pizacani; Wendy G Bjornson; Janet Spradley; Elizabeth Allen; Paul Lees Journal: Nicotine Tob Res Date: 2007-02 Impact factor: 4.244
Authors: Frederick S Barrett; Theresa M Carbonaro; Ethan Hurwitz; Matthew W Johnson; Roland R Griffiths Journal: Psychopharmacology (Berl) Date: 2018-07-30 Impact factor: 4.530
Authors: Matthew W Johnson; Roland R Griffiths; Peter S Hendricks; Jack E Henningfield Journal: Neuropharmacology Date: 2018-06-05 Impact factor: 5.250
Authors: Aboagyewaah Oppong-Damoah; Kristen E Curry; Bruce E Blough; Kenner C Rice; Kevin S Murnane Journal: Psychopharmacology (Berl) Date: 2019-07-15 Impact factor: 4.530